Serum concentrations of paliperidone versus risperidone and clinical effects

Nazirizadeh, Y; Vogel, Frederick; Bader, Wolfgang; Haen, Ekkehard; Pfuhlmann, Bruno; Gründer, Gerhard; Paulzen, Michael; Schwarz, Markus J.; Zernig, Gerald; Hiemke, Christoph

doi:10.1007/s00228-010-0812-7

Cited by 43 publications

(30 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The therapeutic reference ranges as recommended by the TDM group of the AGNP are given in ▶ Table 4. ▶Table 4 Recommended therapeutic reference ranges (consensus), elimination half-life (t1/2) ranges and laboratory alert levels for neuropsychopharmacological drugs and levels of recommendation to use TDM as clinical routine for dose optimization without specific indications (see ▶ [40,110,224,842] Continued.…”

Section: Definitionmentioning

confidence: 99%

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

Bergemann²,

et al. 2017

View full text Add to dashboard Cite

Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of pharmacokinetics and thus enables personalized pharmacotherapy. In psychiatry and neurology, patient populations that may particularly benefit from TDM are children and adolescents, pregnant women, elderly patients, individuals with intellectual disabilities, patients with substance abuse disorders, forensic psychiatric patients or patients with known or suspected pharmacokinetic abnormalities. Non-response at therapeutic doses, uncertain drug adherence, suboptimal tolerability, or pharmacokinetic drug-drug interactions are typical indications for TDM. However, the potential benefits of TDM to optimize pharmacotherapy can only be obtained if the method is adequately integrated in the clinical treatment process. To supply treating physicians and laboratories with valid information on TDM, the TDM task force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) issued their first guidelines for TDM in psychiatry in 2004. After an update in 2011, it was time for the next update. Following the new guidelines holds the potential to improve neuropsychopharmacotherapy, accelerate the recovery of many patients, and reduce health care costs.

show abstract

Section: Definitionmentioning

confidence: 99%

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

Bergemann²,

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Because the lithium groups in the survival experiment exhibited greater urination than did the lithium groups in the proliferation experiment (we hypothesize that this was the result of the longer duration of lithium treatment), we suspect that this affected the rate of paliperidone excretion in these animals (Mannens et al, 1993). Mean peak to trough ratio of paliperidone (Invega) in humans is 1.7 according to manufacturer's instructions (Janssen Pharmaceutica), with the trough 75th percentile of serum concentrations being 52 ng/ml (middle 50th percentile 20 -52 ng/ml) (Nazirizadeh et al, 2010).…”

Section: Resultsmentioning

confidence: 99%

Lithium, but Not Fluoxetine or the Corticotropin-Releasing Factor Receptor 1 Receptor Antagonist R121919, Increases Cell Proliferation in the Adult Dentate Gyrus

Hanson

Nemeroff

Owens

2011

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Several antidepressant drugs have previously been reported to increase neurogenesis in the dentate gyrus of the hippocampus in laboratory animals. We found no effect of the selective serotonin reuptake inhibitor fluoxetine or the corticotropin-releasing factor receptor 1 antagonist R121919 [3-on the rate of cell proliferation or hippocampal brain-derived neurotrophic factor (BDNF) mRNA expression in either adult or adolescent rats after long-term administration. In adults, the mood stabilizer lithium was found to significantly increase cell proliferation; the atypical antipsychotic paliperidone did not affect proliferation, either alone or when combined with lithium. Fourteen-day survival of neuronally fated cells showed a significant interaction effect of lithium and paliperidone but no effect of either drug alone. BDNF mRNA expression was significantly decreased by lithium in the CA1/2 cell fields and increased by paliperidone in the CA1/2, CA3, and dentate gyrus. These results raise questions concerning the hypothesis that all antidepressants increase neurogenesis under nonstressed conditions. They also confirm and extend previous reports of lithium-induced increases in cell proliferation but not survival.

show abstract

“…42 Studies with clozapine showed doubtful correlations between blood concentrations and clinical response, but they did identify a concentration threshold cut-off or a therapeutic window to validate the use of therapeutic drug monitoring. [43][44][45][46][47][48][49] No correlation was found between blood levels and clinical effect for risperidone and paliperidone (9-hydroxyrisperidone), [50][51][52][53][54][55][56][57] although an unreplicated study found a therapeutic window. 51 Plasma levels of ziprasidone are unpredictably related to dose and do not correlate with symptom improvement, except for negative symptoms assessed with the PANSS.…”

Section: Discussionmentioning

confidence: 99%